Martin-Iglesias D, et al. - Investigators examined 110 subjects and 195 eyes to delineate the retinal changes over a 5-year period [examined by spectral domain-optical coherence tomography (SD-OCT)] in subjects from the Lupus-Cruces cohort treated with hydroxychloroquine (HCQ). They detected no cases of HCQ toxicity. They observed that 99% of subjects were given a daily dose of HCQ ≤5 mg/kg/day at the time of the second SD-OCT. They recorded significantly lower mean Average macular thickness (AMT) and ganglion cell layer thickness (GCLT) in both eyes at the second SD-OCT. Although, all the differences were found clinically insignificant at less than 1%. They noticed similar outcomes among subjects with risk factors for retinopathy. Overall, they supported the safety of long-term HCQ at doses ≤5 mg/kg/day.